Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Oct;20(4):487–490. doi: 10.1128/aac.20.4.487

Clinical Pharmacology of Cefotaxime in Pediatric Patients

Dimitris A Kafetzis 1, D Craig Brater 2,3, John Kanarios 1, Constantine A Sinaniotis 1, Constantine J Papadatos 1
PMCID: PMC181728  PMID: 6282194

Abstract

Cefotaxime is a new cephalosporin with a spectrum of activity which may make it appropriate for use in pediatric patients. In 33 infants and children, administration of cefotaxime resulted in cure or improvement in 97% of patients, with eradication of 94% of isolated pathogens. Toxicity was minimal. The disposition of cefotaxime in this age group was similar to that reported for adults, with an elimination half-life of approximately 1.5 h, a volume of distribution of 1 liter/kg, a total serum clearance of 10 ml/min per kg, and a renal clearance of 6 ml/min per kg.

Full text

PDF
487

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  2. Chamberlain J., Coombes J. D., Dell D., Fromson J. M., Ings R. J., Macdonald C. M., McEwen J. Metabolism of cefotaxime in animals and man. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):69–78. doi: 10.1093/jac/6.suppl_a.69. [DOI] [PubMed] [Google Scholar]
  3. Drasar F. A., Farrell W., Howard A. J., Hince C., Leung T., Williams J. D. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods. J Antimicrob Chemother. 1978 Sep;4(5):445–450. doi: 10.1093/jac/4.5.445. [DOI] [PubMed] [Google Scholar]
  4. Fillastre J. P., Leroy A., Humbert G., Godin M. Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):103–111. doi: 10.1093/jac/6.suppl_a.103. [DOI] [PubMed] [Google Scholar]
  5. Fu K. P., Aswapokee P., Ho I., Matthijssen C., Neu H. C. Pharmacokinetics of cefotaxime. Antimicrob Agents Chemother. 1979 Nov;16(5):592–597. doi: 10.1128/aac.16.5.592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hamilton-Miller J. M., Brumfitt W., Reynolds A. V. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. J Antimicrob Chemother. 1978 Sep;4(5):437–444. doi: 10.1093/jac/4.5.437. [DOI] [PubMed] [Google Scholar]
  7. Lüthy R., Münch R., Blaser J., Bhend H., Siegenthaler W. Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrob Agents Chemother. 1979 Aug;16(2):127–133. doi: 10.1128/aac.16.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Papadatos C. J., Kafetzis D. A., Kanarios J. Cefotaxime in the treatment of severe paediatric infections. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):243–248. doi: 10.1093/jac/6.suppl_a.243. [DOI] [PubMed] [Google Scholar]
  9. Reeves D. S., White L. O., Holt H. A., Bahari D., Bywater M. J., Bax R. P. Human metabolism of cefotaxime. J Antimicrob Chemother. 1980 Sep;6 (Suppl A):93–101. doi: 10.1093/jac/6.suppl_a.93. [DOI] [PubMed] [Google Scholar]
  10. Sedman A. J., Wagner J. G. CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1976 Jul;65(7):1006–1010. doi: 10.1002/jps.2600650713. [DOI] [PubMed] [Google Scholar]
  11. Wise R., Rollason T., Logan M., Andrews J. M., Bedford K. A. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother. 1978 Dec;14(6):807–811. doi: 10.1128/aac.14.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES